Identification

Name
Losartan
Accession Number
DB00678  (APRD00052)
Type
Small Molecule
Groups
Approved
Description

Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.

Structure
Thumb
Synonyms
  • (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
  • 2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
  • DuP 89
  • Losartan
External IDs
HGP-1405 / HGP1405 / MK594
Product Ingredients
IngredientUNIICASInChI Key
Losartan Potassium3ST302B24A124750-99-8OXCMYAYHXIHQOA-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LosartanTablet100 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet50 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet25 mgOralActavis Pharma Company2012-01-25Not applicableCanada
CozaarTablet, film coated50 mg/1Oralbryant ranch prepack1995-04-14Not applicableUs
CozaarTablet, film coated50 mg/1OralMerck Sharp & Dohme Limited1995-04-14Not applicableUs
CozaarTablet25 mg/1OralRemedy Repack2011-04-072016-10-13Us
CozaarTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1995-04-14Not applicableUs00006 0960 54 nlmimage10 c31361ab
CozaarTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2004-06-02Not applicableUs
CozaarTablet, film coated25 mg/1OralRemedy Repack2011-05-192016-10-13Us
CozaarTablet25 mgOralMerck Ltd.1995-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ag-losartanTablet25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-losartanTablet50 mgOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartanTablet25 mgOralApotex Corporation2012-04-13Not applicableCanada
Apo-losartanTablet100 mgOralApotex Corporation2012-01-25Not applicableCanada
Auro-losartanTablet50.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet25.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet100.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Bio-losartanTablet25 mgOralBiomed Pharma2016-05-09Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Losartan/hctLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Act Losartan/hctLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Act Losartan/hctLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Apo-losartan/hctzLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartan/hctzLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartan/hctzLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Auro-losartan HctLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-losartan HctLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-losartan HctLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
HyzaarLosartan Potassium (50 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralMerck Sharp & Dohme Limited1995-04-28Not applicableUs
International/Other Brands
Lortaan
Categories
UNII
JMS50MPO89
CAS number
114798-26-4
Weight
Average: 422.911
Monoisotopic: 422.162187095
Chemical Formula
C22H23ClN6O
InChI Key
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
IUPAC Name
[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol
SMILES
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

Pharmacology

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.

Structured Indications
Pharmacodynamics

Losartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of action

Losartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Losartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases.

Volume of distribution
  • 34 L [losartan, healthy subjects]
  • 12 L [active metabolite, healthy subjects]
Protein binding

99.7% protein bound, primarily to albumin

Metabolism

Hepatic. Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the pharmacologic effects of this medication.

Route of elimination

Following oral administration of losartan, 35% of the dose is recovered in the urine and about 60% in the feces. Following an intravenous dose, 45% is recovered in the urine and 50% in the feces.

Half life

The terminal t1/2 of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.

Clearance
  • Total plasma clearance = 600 mL/min [losartan]
  • Total plasma clearance = 50 mL/min [active metabolite]
  • Renal clearance = 75 mL/min [losartan]
  • Renal clearance = 25 mL/min [active metabolite]
Toxicity

Hypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Losartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Losartan is combined with (4R)-limonene.Investigational
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Losartan can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Losartan can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Losartan.Experimental
AbirateroneThe serum concentration of Losartan can be increased when it is combined with Abiraterone.Approved
AcebutololLosartan may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Losartan.Approved, Investigational
AcemetacinThe therapeutic efficacy of Losartan can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Losartan.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Losartan.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Losartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Losartan is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Losartan.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Losartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Losartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Losartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Alminoprofen.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Losartan.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Losartan.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Losartan.Approved, Illicit, Investigational
AlprenololLosartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanLosartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineLosartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideLosartan may increase the hyperkalemic activities of Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Losartan.Approved, Withdrawn
AmiodaroneThe metabolism of Losartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Losartan.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Losartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Losartan.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Losartan.Approved, Investigational
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Losartan.Approved, Investigational
AmorolfineThe metabolism of Losartan can be decreased when combined with Amorolfine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Losartan.Approved, Illicit, Investigational
Amphotericin BThe metabolism of Losartan can be decreased when combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Losartan.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Losartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Losartan is combined with Andrographolide.Investigational
AnidulafunginThe metabolism of Losartan can be decreased when combined with Anidulafungin.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Losartan is combined with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Losartan.Approved, Investigational
ApalutamideThe serum concentration of Losartan can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Losartan.Approved
ApocyninThe risk or severity of adverse effects can be increased when Losartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Losartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Losartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Losartan is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Losartan can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Losartan.Experimental
ArdeparinArdeparin may increase the hyperkalemic activities of Losartan.Approved, Investigational, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Losartan.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Losartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Losartan.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Losartan.Approved, Investigational
ArtemetherThe metabolism of Losartan can be decreased when combined with Artemether.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Losartan.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Losartan can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Losartan.Approved
AtomoxetineThe metabolism of Losartan can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Losartan is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the antihypertensive activities of Losartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Losartan.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Losartan is combined with Azilsartan medoxomil.Approved, Investigational
Bafilomycin A1The metabolism of Losartan can be decreased when combined with Bafilomycin A1.Experimental
BalsalazideThe risk or severity of adverse effects can be increased when Losartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Losartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Losartan.Illicit
BarnidipineLosartan may increase the antihypertensive activities of Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Losartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Losartan is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Losartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Losartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Losartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Benoxaprofen.Withdrawn
Benzoic AcidThe metabolism of Losartan can be decreased when combined with Benzoic Acid.Approved, Investigational
BenzydamineThe risk or severity of adverse effects can be increased when Losartan is combined with Benzydamine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Losartan.Approved
BepridilLosartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Losartan.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Losartan.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Losartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Losartan is combined with Bevonium.Experimental
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Losartan.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Losartan.Experimental
BifonazoleThe metabolism of Losartan can be decreased when combined with Bifonazole.Approved, Investigational
BimatoprostLosartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Losartan.Approved
BoceprevirThe metabolism of Losartan can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Losartan can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Losartan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Losartan.Approved
BQ-123Losartan may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe metabolism of Losartan can be decreased when combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.Approved, Investigational
BretyliumLosartan may increase the hypotensive activities of Bretylium.Approved
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Losartan.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Losartan.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Losartan.Approved, Investigational
BrofaromineBrofaromine may increase the hypotensive activities of Losartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Losartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Losartan.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Losartan.Approved
BucillamineThe risk or severity of adverse effects can be increased when Losartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Losartan is combined with Bufexamac.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Losartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Losartan.Approved, Investigational
BupranololLosartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Losartan.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Losartan.Approved
ButenafineThe metabolism of Losartan can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Losartan can be decreased when combined with Butoconazole.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Losartan.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Losartan.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Losartan.Approved, Investigational
CadralazineCadralazine may increase the hypotensive activities of Losartan.Experimental
CafedrineLosartan may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Losartan.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Losartan.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Losartan.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Losartan.Approved
CandicidinThe metabolism of Losartan can be decreased when combined with Candicidin.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Losartan is combined with Candoxatril.Experimental
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Losartan.Approved, Investigational
CapecitabineThe metabolism of Losartan can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe metabolism of Losartan can be decreased when combined with Capric acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Losartan can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Losartan is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Losartan.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Losartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Losartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Losartan.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Losartan.Approved, Investigational
CaspofunginThe metabolism of Losartan can be decreased when combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Losartan is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Losartan.Approved, Investigational
CeliprololLosartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Losartan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Losartan.Approved, Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
CeruleninThe metabolism of Losartan can be decreased when combined with Cerulenin.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
ChlorothiazideLosartan may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChloroxineThe metabolism of Losartan can be decreased when combined with Chloroxine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Losartan.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Losartan.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Losartan.Approved
CholecalciferolThe metabolism of Losartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Choline magnesium trisalicylate.Approved
CicletanineLosartan may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe metabolism of Losartan can be decreased when combined with Ciclopirox.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Losartan.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Losartan.Approved, Investigational
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Losartan.Approved, Investigational
CiprofloxacinLosartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Losartan can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Losartan can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Losartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Losartan.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Losartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Losartan is combined with Clonixin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Losartan.Approved
CloranololLosartan may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Losartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Losartan.Approved
CobicistatThe metabolism of Losartan can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Losartan.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Losartan.Approved, Investigational
CordycepinThe metabolism of Losartan can be decreased when combined with Cordycepin.Investigational
CrisaboroleThe metabolism of Losartan can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Losartan can be decreased when combined with Crizotinib.Approved
CryptenamineLosartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Losartan is combined with Curcumin.Approved, Investigational
CyclopenthiazideLosartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Losartan.Approved, Investigational
CyclosporineThe metabolism of Losartan can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Losartan.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Losartan.Approved
DabrafenibThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Losartan.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Losartan.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Losartan.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Losartan.Approved, Investigational
DarunavirThe metabolism of Losartan can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Losartan.Approved
DasatinibThe serum concentration of Losartan can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Losartan.Approved, Investigational
DeferasiroxThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Delapril.Experimental
DelavirdineThe metabolism of Losartan can be decreased when combined with Delavirdine.Approved
DeserpidineLosartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Losartan.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Losartan.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Losartan.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Losartan.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Losartan.Approved
DichloropheneThe metabolism of Losartan can be decreased when combined with Dichlorophene.Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Losartan.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Losartan is combined with Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Losartan.Approved
DiethylnorspermineLosartan may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Losartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Losartan is combined with Diflunisal.Approved, Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Losartan.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Losartan.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Losartan.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Losartan.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Losartan.Approved, Investigational
DiltiazemThe metabolism of Losartan can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Losartan.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Losartan is combined with Dipyridamole.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Losartan.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Losartan.Approved, Investigational
DomperidoneThe metabolism of Domperidone can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Losartan.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Losartan.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Losartan.Approved
DosulepinThe metabolism of Losartan can be decreased when combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Losartan.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Losartan.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Losartan.Approved, Investigational
DoxycyclineThe metabolism of Losartan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Losartan.Approved, Illicit
DronedaroneThe metabolism of Losartan can be decreased when combined with Dronedarone.Approved
DrospirenoneLosartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Droxicam.Withdrawn
DuloxetineLosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Losartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Losartan is combined with E-6201.Investigational
EconazoleThe metabolism of Losartan can be decreased when combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Losartan.Approved
EfavirenzThe metabolism of Losartan can be decreased when combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Losartan can be decreased when combined with Efinaconazole.Approved
EfonidipineLosartan may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Losartan.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Losartan.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Losartan.Approved, Investigational
EndralazineEndralazine may increase the hypotensive activities of Losartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Losartan.Approved
EnzalutamideThe serum concentration of Losartan can be decreased when it is combined with Enzalutamide.Approved
EpanololLosartan may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Losartan.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Losartan.Approved
EprosartanLosartan may increase the hypotensive activities of Eprosartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Losartan.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Losartan.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Losartan.Approved, Investigational
ErythromycinThe metabolism of Losartan can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Losartan.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Losartan.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Losartan.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Losartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Losartan is combined with Ethenzamide.Experimental
EtodolacThe metabolism of Etodolac can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Losartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Losartan.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Losartan.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Losartan is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Losartan.Approved
ExisulindThe risk or severity of adverse effects can be increased when Losartan is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Losartan is combined with Felbinac.Experimental
FelodipineThe metabolism of Losartan can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenbufen.Approved
FenoldopamLosartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Losartan is combined with Fentiazac.Experimental
FenticonazoleThe metabolism of Losartan can be decreased when combined with Fenticonazole.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Feprazone.Experimental
Ferulic acidLosartan may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Losartan.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Losartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Losartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Losartan can be decreased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe metabolism of Losartan can be decreased when combined with Flucytosine.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Losartan.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Losartan.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Losartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Losartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Losartan.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Losartan.Approved, Investigational
FlutrimazoleThe metabolism of Losartan can be decreased when combined with Flutrimazole.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Losartan.Approved
FluvoxamineThe metabolism of Losartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Losartan.Approved, Investigational
FosamprenavirThe metabolism of Losartan can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Losartan can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Losartan can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Losartan.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Losartan can be increased when it is combined with Fusidic Acid.Approved, Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Losartan.Investigational
GemfibrozilThe metabolism of Losartan can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Losartan.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Losartan.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Losartan.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Losartan.Approved
GlyphosateThe metabolism of Losartan can be decreased when combined with Glyphosate.Experimental
GriseofulvinThe metabolism of Losartan can be decreased when combined with Griseofulvin.Approved, Investigational, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Losartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Losartan.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Losartan.Approved
GuanazodineLosartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineLosartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Losartan.Approved, Investigational
GuanoclorLosartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLosartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLosartan may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe metabolism of Losartan can be decreased when combined with Hachimycin.Experimental
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Losartan.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Losartan.Approved
HaloproginThe metabolism of Losartan can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Losartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Losartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
HexamethoniumLosartan may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe metabolism of Losartan can be decreased when combined with Hexetidine.Approved, Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Losartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Losartan is combined with Higenamine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Losartan.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Losartan.Experimental
HydralazineHydralazine may increase the hypotensive activities of Losartan.Approved
HydrochlorothiazideLosartan may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideLosartan may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Losartan.Approved, Illicit
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Losartan.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Losartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Losartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Losartan is combined with Icatibant.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Losartan.Approved
IdelalisibThe metabolism of Losartan can be decreased when combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Losartan.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Losartan.Approved, Investigational
ImatinibThe metabolism of Losartan can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Losartan.Approved
IndapamideLosartan may increase the hypotensive activities of Indapamide.Approved
IndenololLosartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Losartan can be decreased when combined with Indinavir.Approved
IndisulamThe metabolism of Indisulam can be decreased when combined with Losartan.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Losartan is combined with Indobufen.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Losartan.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Losartan.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Losartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Losartan.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Losartan.Approved, Investigational
IsavuconazoleThe serum concentration of Losartan can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Losartan can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Losartan.Approved
IsoconazoleThe metabolism of Losartan can be decreased when combined with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Losartan.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Losartan can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Losartan can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Losartan can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Losartan.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Losartan is combined with Kebuzone.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Losartan.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Losartan.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Losartan.Approved, Investigational
KetoconazoleThe metabolism of Losartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Losartan.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Losartan is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Losartan.Approved
LacidipineLosartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Losartan.Approved, Investigational
LapatinibThe metabolism of Losartan can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Losartan.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Losartan.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Losartan.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Losartan.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Losartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Losartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Losartan.Approved, Investigational
LevodopaLosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Losartan.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Losartan.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Losartan.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Losartan.Approved, Vet Approved
LinsidomineLosartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Losartan is combined with Lisofylline.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Losartan.Approved, Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Losartan.Approved
LobeglitazoneThe metabolism of Losartan can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineLosartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Losartan is combined with Lonazolac.Experimental
LoperamideThe metabolism of Loperamide can be decreased when combined with Losartan.Approved
LopinavirThe metabolism of Losartan can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Losartan.Approved, Investigational
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Losartan.Approved, Investigational
LorpiprazoleThe serum concentration of Losartan can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Losartan.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Losartan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Losartan can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Losartan.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Losartan.Illicit, Investigational, Withdrawn
MacitentanLosartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Magnesium salicylate.Approved
ManidipineLosartan may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Losartan is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Losartan.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Losartan.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.Approved, Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Losartan.Experimental
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Losartan.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Losartan.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Losartan.Approved, Vet Approved
MepartricinThe metabolism of Losartan can be decreased when combined with Mepartricin.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Losartan.Investigational, Withdrawn
MesalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Losartan.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Metamizole.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Losartan.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Losartan.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Losartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Losartan.Approved
MethoserpidineLosartan may increase the hypotensive activities of Methoserpidine.Experimental
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.Approved
MethyldopaLosartan may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Losartan.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Losartan.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Losartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Losartan.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Losartan.Approved
MetipranololLosartan may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Losartan.Approved
MetoprololMetoprolol may increase the hypotensive activities of Losartan.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Losartan.Approved
MetyrosineLosartan may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe metabolism of Losartan can be decreased when combined with Mevastatin.Experimental
MibefradilLosartan may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MicafunginThe metabolism of Losartan can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Losartan can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Losartan can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Losartan can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Losartan can be decreased when combined with Miltefosine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Losartan.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Losartan.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Losartan.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Losartan.Approved
MitotaneThe serum concentration of Losartan can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Losartan is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Losartan.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Losartan.Approved, Investigational
MonensinThe metabolism of Losartan can be decreased when combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Losartan.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Losartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Losartan.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be decreased when combined with Losartan.Investigational
MuzolimineLosartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Losartan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.Approved
MyxothiazolThe metabolism of Losartan can be decreased when combined with Myxothiazol.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Losartan.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Losartan.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Losartan is combined with Nabumetone.Approved
NadololLosartan may increase the hypotensive activities of Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Losartan is combined with Nafamostat.Approved, Investigational
NaftifineThe metabolism of Losartan can be decreased when combined with Naftifine.Approved
NaftopidilLosartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Losartan.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Losartan.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Losartan.Approved, Vet Approved
NatamycinThe metabolism of Losartan can be decreased when combined with Natamycin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Losartan.Approved, Investigational
NebivololLosartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Losartan can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Losartan can be decreased when combined with Nelfinavir.Approved
NepafenacThe risk or severity of adverse effects can be increased when Losartan is combined with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Losartan is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Losartan can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Losartan can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Losartan.Withdrawn
NicardipineThe metabolism of Losartan can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Losartan.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
NicorandilNicorandil may increase the hyperkalemic activities of Losartan.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Losartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Losartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Niflumic Acid.Approved
NifuratelThe metabolism of Losartan can be decreased when combined with Nifuratel.Experimental
NiguldipineLosartan may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe metabolism of Losartan can be decreased when combined with Nikkomycin Z.Investigational
NilotinibThe metabolism of Losartan can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineLosartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Losartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Losartan.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Losartan.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Losartan.Approved
NitrendipineLosartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Losartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Losartan.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Losartan.Approved, Investigational
NitroxolineThe metabolism of Losartan can be decreased when combined with Nitroxoline.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Losartan.Approved
NystatinThe metabolism of Losartan can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabLosartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Losartan.Withdrawn
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Losartan.Investigational
OlaparibThe metabolism of Losartan can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Losartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Losartan.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Losartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Losartan is combined with Omapatrilat.Investigational
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Losartan.Approved, Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
OmoconazoleThe metabolism of Losartan can be decreased when combined with Omoconazole.Experimental
OndansetronThe metabolism of Ondansetron can be decreased when combined with Losartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Losartan is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Losartan can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Losartan.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Losartan.Approved
OxiconazoleThe metabolism of Losartan can be decreased when combined with Oxiconazole.Approved
OxprenololLosartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Losartan.Approved, Vet Approved
PafuramidineThe metabolism of Losartan can be decreased when combined with Pafuramidine.Investigational
PalbociclibThe serum concentration of Losartan can be increased when it is combined with Palbociclib.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Losartan.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Losartan.Approved
PargylinePargyline may increase the hypotensive activities of Losartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Losartan is combined with Parthenolide.Approved, Investigational
Patent BlueThe therapeutic efficacy of Losartan can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Losartan.Approved
PenbutololLosartan may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Losartan can be decreased when combined with Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Losartan can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumLosartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Losartan.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Losartan.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Losartan.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Losartan.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Losartan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Losartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Losartan.Withdrawn
PhenobarbitalThe metabolism of Losartan can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineLosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Losartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Losartan.Approved, Investigational
PhentolamineLosartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Losartan.Approved, Vet Approved
PhenytoinThe metabolism of Losartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Losartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Losartan.Approved
PindololLosartan may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Losartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Losartan.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Losartan.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Losartan is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Losartan.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Losartan.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Losartan.Approved
PitolisantThe serum concentration of Losartan can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Losartan.Withdrawn
Platelet Activating FactorLosartan may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideLosartan may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Losartan.Approved, Investigational
PosaconazoleThe metabolism of Losartan can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Losartan.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Pranoprofen.Experimental, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Losartan.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Losartan.Approved
PrazosinPrazosin may increase the hypotensive activities of Losartan.Approved
PrimidoneThe metabolism of Losartan can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Losartan.Approved, Investigational
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Losartan.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Losartan is combined with Proglumetacin.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Losartan.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Losartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Losartan is combined with Propacetamol.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Losartan.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Proquazone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Losartan.Approved
PTC299The risk or severity of adverse effects can be increased when Losartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Losartan can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyrrolnitrinThe metabolism of Losartan can be decreased when combined with Pyrrolnitrin.Experimental
QuazepamThe metabolism of Quazepam can be decreased when combined with Losartan.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Losartan.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Losartan.Approved
RabeprazoleThe metabolism of Losartan can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe metabolism of Losartan can be decreased when combined with Radicicol.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Losartan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Losartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Losartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Losartan.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Losartan.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Losartan is combined with Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Losartan.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
RifabutinThe metabolism of Losartan can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Losartan can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Losartan can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Losartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Losartan.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Losartan.Approved
RiociguatThe metabolism of Riociguat can be decreased when combined with Losartan.Approved
RisperidoneLosartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabLosartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Losartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Losartan.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Losartan.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Losartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Losartan.Approved
RucaparibThe metabolism of Losartan can be decreased when combined with Rucaparib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Losartan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Losartan.Approved
SafrazineSafrazine may increase the hypotensive activities of Losartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide.Approved
Salicylhydroxamic AcidThe metabolism of Losartan can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Losartan can be decreased when combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Losartan is combined with Salsalate.Approved
SaprisartanLosartan may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Losartan can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Losartan can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Losartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Losartan.Approved
SemapimodThe risk or severity of adverse effects can be increased when Losartan is combined with Semapimod.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Losartan.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Losartan is combined with Serrapeptase.Investigational
SertaconazoleThe metabolism of Losartan can be decreased when combined with Sertaconazole.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Losartan.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Losartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Losartan.Approved
SiltuximabThe serum concentration of Losartan can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Losartan can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Losartan.Approved
SinefunginThe metabolism of Losartan can be decreased when combined with Sinefungin.Experimental
SirolimusThe metabolism of Losartan can be decreased when combined with Sirolimus.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Losartan.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
Sodium phosphateLosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SorafenibThe metabolism of Losartan can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Losartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Losartan.Approved
SRT501The risk or severity of adverse effects can be increased when Losartan is combined with SRT501.Investigational
St. John's WortThe serum concentration of Losartan can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Losartan can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Losartan.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Losartan.Approved, Investigational
SulconazoleThe metabolism of Losartan can be decreased when combined with Sulconazole.Approved
SulfadiazineThe metabolism of Losartan can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Losartan.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Losartan.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Losartan.Approved
SulfisoxazoleThe metabolism of Losartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Losartan is combined with Sulindac.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Losartan.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Losartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Losartan.Approved, Investigational
TalinololLosartan may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Losartan.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Losartan.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Losartan.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Losartan is combined with Tarenflurbil.Investigational
TavaboroleThe metabolism of Losartan can be decreased when combined with Tavaborole.Approved, Investigational
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Losartan.Approved, Investigational
TelaprevirThe metabolism of Losartan can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Losartan can be decreased when combined with Telithromycin.Approved
TelmisartanLosartan may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Losartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Losartan is combined with Tenidap.Experimental
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Losartan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Losartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Losartan is combined with Terazosin.Approved
TerbinafineThe metabolism of Losartan can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Losartan can be decreased when combined with Terconazole.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Losartan.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Losartan.Experimental
TeriflunomideThe metabolism of Losartan can be decreased when combined with Teriflunomide.Approved
TerlipressinLosartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Losartan.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Losartan.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Losartan.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Losartan.Approved, Investigational
TetrahydropalmatineLosartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
TheodrenalineLosartan may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Losartan.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Losartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Losartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Losartan.Approved, Withdrawn
ThymolThe metabolism of Losartan can be decreased when combined with Thymol.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Tiaprofenic acid.Approved
TiboloneLosartan may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Losartan can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Losartan can be decreased when combined with Ticlopidine.Approved
TicrynafenLosartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Losartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Losartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Losartan.Approved
TioconazoleThe metabolism of Losartan can be decreased when combined with Tioconazole.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Losartan.Approved, Investigational
TocilizumabThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.Approved
TolazolineLosartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Losartan can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Losartan.Approved, Withdrawn
TolciclateThe metabolism of Losartan can be decreased when combined with Tolciclate.Experimental
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Losartan is combined with Tolmetin.Approved
TolnaftateThe metabolism of Losartan can be decreased when combined with Tolnaftate.Approved, Investigational, Vet Approved
TolonidineLosartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Losartan.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Losartan.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Losartan.Approved
TopiroxostatThe metabolism of Losartan can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Losartan.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Losartan.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Losartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Losartan is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Losartan.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Losartan.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Losartan.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Losartan.Approved, Investigational, Nutraceutical
TriamtereneLosartan may increase the hyperkalemic activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Losartan is combined with Tribenoside.Experimental
TrichlormethiazideLosartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Losartan.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Losartan.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Losartan.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Losartan.Approved, Vet Approved
TrimetrexateThe metabolism of Losartan can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Losartan.Approved
TriptolideThe risk or severity of adverse effects can be increased when Losartan is combined with Triptolide.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Losartan.Investigational, Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
UnoprostoneLosartan may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Losartan.Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Losartan.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Losartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Losartan.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Losartan.Approved, Investigational
VemurafenibThe serum concentration of Losartan can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Losartan can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Losartan can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Losartan.Investigational
VincamineLosartan may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Losartan.Approved, Investigational
VinpocetineLosartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Losartan.Approved, Investigational
VoriconazoleThe metabolism of Losartan can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Losartan.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Losartan.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Losartan.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
XipamideLosartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineLosartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Losartan.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Losartan can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Losartan.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Losartan.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Losartan.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Losartan can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Losartan.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Losartan is combined with Zomepirac.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Losartan.Approved
Food Interactions
  • Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.

References

Synthesis Reference

Gordon C. Campbell, Jr., Anil M. Dwivedi, Dorothy A. Levorse, James A. McCauley, Krishnaswamy S. Raghavan, "Polymorphs of losartan and the process for the preparation of form II of losartan." U.S. Patent US5608075, issued May, 1994.

US5608075
General References
  1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. [PubMed:11937178]
  2. Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat]. Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8. [PubMed:12895325]
  3. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21. [PubMed:16601194]
  4. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  5. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660]
  6. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328]
External Links
Human Metabolome Database
HMDB0014816
KEGG Drug
D08146
KEGG Compound
C07072
PubChem Compound
3961
PubChem Substance
46506538
ChemSpider
3824
BindingDB
82258
ChEBI
6541
ChEMBL
CHEMBL191
Therapeutic Targets Database
DAP000523
PharmGKB
PA450268
IUPHAR
590
Guide to Pharmacology
GtP Drug Page
HET
LSN
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Losartan
ATC Codes
C09DA01 — Losartan and diureticsC09DB06 — Losartan and amlodipineC09CA01 — Losartan
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
PDB Entries
5x23 / 5x24 / 5xxi
FDA label
Download (212 KB)
MSDS
Download (19 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePeripheral Arterial Disease (PAD)1
0CompletedDiagnosticPostural Tachycardia Syndrome1
0CompletedTreatmentDiabetic Nephropathies1
0CompletedTreatmentSickle Cell Disorders1
0Not Yet RecruitingOtherCystic Fibrosis (CF)1
0Not Yet RecruitingTreatmentBlood Pressures / High Blood Pressure (Hypertension)1
1CompletedNot AvailableHealthy Volunteers11
1CompletedNot AvailableKidney Diseases1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHypertension(HTN)1
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedDiagnosticHigh Blood Pressure (Hypertension)1
1CompletedHealth Services ResearchHealthy Volunteers2
1CompletedTreatmentCardiovascular Disease (CVD)1
1CompletedTreatmentFasting1
1CompletedTreatmentHigh Blood Pressure (Hypertension)4
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
1RecruitingOtherHealthy Volunteers1
1TerminatedBasic ScienceHigh Blood Pressure (Hypertension) / Multiple System Atrophy (MSA) / Progressive autonomic failure1
1Unknown StatusTreatmentHealthy Volunteers1
1, 2CompletedTreatmentAging1
1, 2RecruitingTreatmentChildren / Pulmonary vein stenosis1
1, 2RecruitingTreatmentDisseminated Sclerosis1
1, 2RecruitingTreatmentHamstring Injury1
1, 2TerminatedTreatmentAlbinism, Oculocutaneous / Hermansky-Pudlak Syndrome (HPS) / Metabolic Diseases / Platelet Storage Pool Deficiency / Pulmonary Fibrosis1
2Active Not RecruitingPreventionHigh Blood Pressure (Hypertension) / Hyperlipidemias1
2Active Not RecruitingPreventionInflammatory Reaction1
2Active Not RecruitingTreatmentConnective Tissue Disorders / Oesophagitis, Eosinophilic1
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedPreventionSarcopenia1
2CompletedTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension) / Hyperkalemia1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentHigh Blood Pressure (Hypertension)1
2CompletedTreatmentHigh Blood Pressure (Hypertension) / Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour)1
2CompletedTreatmentHypertrophic Cardiomyopathy2
2CompletedTreatmentMarfan Syndrome1
2CompletedTreatmentNAFLD1
2CompletedTreatmentRenal Dysfunction / Sickle Cell Disorders1
2CompletedTreatmentTransplant, Kidney1
2Not Yet RecruitingTreatmentNAFLD - Nonalcoholic Fatty Liver Disease1
2RecruitingPreventionAging / High Blood Pressure (Hypertension) / Sedentary Lifestyle1
2RecruitingPreventionStress Disorders, Post-Traumatic1
2RecruitingTreatmentCystic Fibrosis (CF)1
2RecruitingTreatmentHeart Defects,Congenital / Tetralogy Of Fallot / Ventricular Dysfunction, Right1
2RecruitingTreatmentHigh Blood Pressure (Hypertension)2
2RecruitingTreatmentHigh Blood Pressure (Hypertension) / Kidney Diseases / Proteinuria / Sickle Cell Disorders1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2RecruitingTreatmentOesophagitis, Eosinophilic1
2TerminatedTreatmentHigh Blood Pressure (Hypertension)1
2TerminatedTreatmentHigh Blood Pressure (Hypertension) / Unspecified Adult Solid Tumor, Protocol Specific1
2TerminatedTreatmentPre-Diabetic / Pre-Hypertension1
2Unknown StatusPreventionMarfan Syndrome1
2Unknown StatusTreatmentHypertension,Essential1
2Unknown StatusTreatmentNonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis1
2, 3CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF) / Pulmonary Fibrosis1
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / High Blood Pressure (Hypertension) / Subjective Cognitive Decline1
2, 3TerminatedTreatmentDiabetic Nephropathies1
2, 3WithdrawnTreatmentHigh Blood Pressure (Hypertension)1
3Active Not RecruitingTreatmentNewly-diagnosed Glioblastoma1
3CompletedPreventionLung Cancers / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentArterial Hypertension1
3CompletedTreatmentBMI >27 kg/m2 / High Blood Pressure (Hypertension) / Left Ventricular Hypertrophy1
3CompletedTreatmentCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
3CompletedTreatmentDiabetic Nephropathies1
3CompletedTreatmentDiabetic Nephropathies / Kidney Diseases / Proteinuria / Type 2 Diabetes Mellitus1
3CompletedTreatmentHeart Failure, Unspecified1
3CompletedTreatmentHigh Blood Pressure (Hypertension)16
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Disorders1
3CompletedTreatmentHyperlipidemias / Hypertension,Essential1
3CompletedTreatmentHypertension,Essential2
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentMarfan Syndrome2
3CompletedTreatmentNonalcoholic Steatohepatitis1
3CompletedTreatmentProteinuria1
3CompletedTreatmentPulmonary Hypertension (PH)1
3Not Yet RecruitingTreatmentGlomerulonephritis, Immunoglobulin A (IgA)1
3Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
3RecruitingTreatmentCerebral Small Vessels Disease1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentHigh Blood Pressure (Hypertension)1
3RecruitingTreatmentIgA Glomerulonephritis1
3RecruitingTreatmentMarfan Syndrome1
3TerminatedTreatmentHigh Blood Pressure (Hypertension)1
3TerminatedTreatmentKidney Diseases / Renal Dysfunction / Type 2 Diabetes Mellitus1
3TerminatedTreatmentMarfan Syndrome1
3Unknown StatusPreventionMarfan Syndrome1
3Unknown StatusTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
3Unknown StatusTreatmentMarfan Syndrome1
3Unknown StatusTreatmentProteinuria1
3Unknown StatusTreatmentSevere Sepsis1
3WithdrawnPreventionHyperoxaluria1
3WithdrawnTreatmentEssential Arterial Hypertension2
4Active Not RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4CompletedNot AvailableBMI >30 kg/m2 / High Blood Pressure (Hypertension) / Hyperglycemias1
4CompletedBasic ScienceRejection, Transplant1
4CompletedDiagnosticHyperaldosteronism1
4CompletedPreventionDiabetic Nephropathies1
4CompletedPreventionKidney Diseases / Proteinuria1
4CompletedPreventionRenal Stones1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis, Liver1
4CompletedTreatmentCongestive Heart Failure (CHF) / Low Cardiac Output1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetic Nephropathies / High Blood Pressure (Hypertension)1
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHigh Blood Pressure (Hypertension)8
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Hypertension,Essential1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Impaired Glucose Tolerance (IGT)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricle Hypertrophy1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Pharmacogenetics1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Sleep Apnea Syndrome1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Strokes1
4CompletedTreatmentInfection, Human Immunodeficiency Virus I1
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentLiver Transplant Recipients1
4CompletedTreatmentMacroalbuminuric Diabetic Nephropathy1
4CompletedTreatmentStage 2 Systolic Hypertension1
4CompletedTreatmentStroke, Ischemic1
4Not Yet RecruitingBasic ScienceArterial hypoxia / Chemoreceptor Apnea / Respiration; Sleep Disorder / Sleep Disordered Breathing (SDB)1
4Not Yet RecruitingTreatmentPediatric Hypertension1
4RecruitingPreventionBlood Pressures / High Blood Pressure (Hypertension) / Strokes1
4RecruitingTreatmentBipolar Disorder (BD) / Cardiovascular Disease (CVD) / Major Depressive Disorder (MDD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Serious Mental Illness1
4RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4RecruitingTreatmentEmphysema1
4RecruitingTreatmentGlomerulonephritis / Proteinuria1
4RecruitingTreatmentIgA Nephropathy1
4SuspendedTreatmentEnd Stage Renal Disease (ESRD) / High Blood Pressure (Hypertension) / Proteinuria1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedPreventionDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4Unknown StatusPreventionAlcoholic Liver Cirrhosis / Ascites1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema / Smoking1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)3
4Unknown StatusTreatmentHypertension, Resistant to Conventional Therapy / Hypertension,Essential1
4Unknown StatusTreatmentHypertension,Essential1
4WithdrawnTreatmentHeart Failure, Unspecified1
Not AvailableActive Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableCompletedNot AvailableAging / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHealthy Normotensive Participants1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)2
Not AvailableCompletedNot AvailableHypertrophic Cardiomyopathy / Left Ventricular Hypertrophy / Myocardial Ischemia1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceInsulin Resistance / Type 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceMemory, Long-Term / Memory, Short-Term1
Not AvailableCompletedDiagnosticHigh Blood Pressure (Hypertension)1
Not AvailableCompletedPreventionLeft Ventricular Hypertrophy / Renal Failure1
Not AvailableCompletedTreatmentAlbuminuria1
Not AvailableCompletedTreatmentAngiotensin II Type 1 Receptor Blockers / Diabetic Nephropathies / Glucose Metabolism / Obese / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Impaired Glucose Tolerance (IGT) / Insulin Resistance / Pre-Diabetic1
Not AvailableCompletedTreatmentDiabetic Nephropathies1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Proteinuria1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Type 2 Diabetes Mellitus2
Not AvailableCompletedTreatmentDuchenne's Muscular Dystrophy (DMD) / Prophylaxis of cardiomyopathy1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)6
Not AvailableCompletedTreatmentMicroalbuminuria1
Not AvailableCompletedTreatmentPrecancerous Conditions1
Not AvailableRecruitingBasic ScienceChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingBasic ScienceHealthy Volunteers1
Not AvailableRecruitingTreatmentIgA Nephropathy1
Not AvailableRecruitingTreatmentPosttraumatic Stress Disorders1
Not AvailableTerminatedScreeningCytochrome P450 Phenotype and Genotype Metrics1
Not AvailableTerminatedTreatmentACE Inhibitor / Angiotensin II Type 1 Receptor Blockers / Dose-Response Relationship, Drug / Progression, Disease / Proteinuria / Renal Insufficiency,Chronic1
Not AvailableTerminatedTreatmentRenal Insufficiency,Chronic1
Not AvailableUnknown StatusNot AvailableAtherosclerosis / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusNot AvailableHigh Blood Pressure (Hypertension)2
Not AvailableUnknown StatusTreatmentAngiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Chronic Kidney Insufficiency / Proteinuria1
Not AvailableUnknown StatusTreatmentBicuspid Aortic Valve (BAV) / Thoracic Aortic Aneurysm (TAA)1
Not AvailableUnknown StatusTreatmentChronic Renal Diseases1
Not AvailableUnknown StatusTreatmentIgA Glomerulonephritis1
Not AvailableUnknown StatusTreatmentNonvalvular Atrial Fibrillation1
Not AvailableWithdrawnSupportive CareDyspnea / Lung Cancers / Pulmonary Complications / Radiation Fibrosis1

Pharmacoeconomics

Manufacturers
  • Merck research laboratories div merck co inc
  • Teva pharmaceuticals usa inc
  • Merck & Co., Inc.
Packagers
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Cardinal Health
  • Dispensing Solutions
  • Ipca Laboratories Ltd.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Merck & Co.
  • Mylan
  • Neuman Distributors Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Remedy Repack
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
TabletOral100.0 mg
TabletOral25.0 mg
TabletOral50.0 mg
TabletOral100 mg
TabletOral25 mg/1
TabletOral25 mg
TabletOral50 mg
TabletOral100 mg/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
TabletOral
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Losartan Potassium 90 50 mg tablet Bottle211.78USD bottle
Losartan Potassium-HCTZ 30 50-12.5 mg tablet Bottle78.05USD bottle
Hyzaar 100-25 mg tablet3.91USD tablet
Hyzaar 100-12.5 mg tablet3.87USD tablet
Hyzaar 100-12.5 tablet3.61USD tablet
Hyzaar 100-25 tablet3.61USD tablet
Losartan Potassium-HCTZ 100-12.5 mg tablet3.54USD tablet
Losartan Potassium-HCTZ 100-25 mg tablet3.54USD tablet
Cozaar 100 mg tablet3.41USD tablet
Losartan potassium 100 mg tablet3.14USD tablet
Hyzaar 50-12.5 mg tablet2.97USD tablet
Hyzaar 50-12.5 tablet2.65USD tablet
Cozaar 50 mg tablet2.5USD tablet
Losartan potassium 50 mg tablet2.26USD tablet
Cozaar 25 mg tablet1.92USD tablet
Losartan potassium 25 mg tablet1.72USD tablet
Cozaar 100 mg Tablet1.31USD tablet
Cozaar 25 mg Tablet1.31USD tablet
Cozaar 50 mg Tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5210079No1993-11-112010-11-11Us
US5608075No1992-03-042009-03-04Us
CA2085584No2003-02-112011-06-07Canada
CA1334092No1995-01-242012-01-24Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)184 °CPhysProp
water solubility0.82 mg/LNot Available
logP6.1Not Available
pKa5.5MERCK INDEX (1996); approx.
Predicted Properties
PropertyValueSource
Water Solubility0.0047 mg/mLALOGPS
logP4.5ALOGPS
logP5.08ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity131.85 m3·mol-1ChemAxon
Polarizability44.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.7812
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6993
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.5309
Renal organic cation transporterNon-inhibitor0.5689
CYP450 2C9 substrateNon-substrate0.6839
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateInhibitor0.5514
CYP450 2C9 inhibitorNon-inhibitor0.5423
CYP450 2D6 inhibitorNon-inhibitor0.8102
CYP450 2C19 inhibitorInhibitor0.6288
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.5382
CarcinogenicityNon-carcinogens0.6595
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6055 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5781
hERG inhibition (predictor II)Inhibitor0.8084
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0000900000-657db16bb4bfe9184114
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-056r-0900000000-43bb8508cd1dbc71bcee
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-55368087829d113fdb7b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-af470646c547613f82a0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-746dcf7a43a3f8839c1d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-0bee80f7ccbc4b68eee0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-d845ae166a10faff242a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-2900000000-d39a309c02e1aaa956b0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-7900000000-d27d10ab008deb157e7a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00fr-0900700000-fef78a7f52d4aa515bb4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00fr-0900600000-c62f0db44e17f79e0c70
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0034900000-22ba49ec64d374c8965e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0191000000-8ff1b5a21f6ef4a462cd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0590000000-9841ff7f881c3e9c11b9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a59-0960000000-a24e287a018dae01dd0d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a5c-0930000000-ff3e675bd445225bf04e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pxu-0920000000-9adf4aef59fc1545fea6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0v00-1900000000-3591888cf5831cbe3d11
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0wmi-2900000000-ab9304c8cebc201d0178
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0j70-5900000000-efa87b7770206ac0ff3e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0491300000-f4b08850a154cfc2117c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0591300000-32a922edf20b3eb76950

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / 1,2,4,5-tetrasubstituted imidazoles / N-substituted imidazoles / Aryl chlorides / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organochlorides
show 2 more
Substituents
Biphenyl / Phenyltetrazole / 1,2,4,5-tetrasubstituted imidazole / Aryl chloride / Aryl halide / N-substituted imidazole / Azole / Heteroaromatic compound / Imidazole / Tetrazole
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, biphenylyltetrazole (CHEBI:6541)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM, Altavilla D, Saitta A: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology. 2004 Mar-Apr;55(2):195-203. [PubMed:15026875]
  3. Dickstein K, Timmermans P, Segal R: Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. Expert Opin Investig Drugs. 1998 Nov;7(11):1897-914. [PubMed:15991937]
  4. Anand-Srivastava MB, Palaparti A: Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors. Can J Physiol Pharmacol. 2003 Feb;81(2):150-8. [PubMed:12710529]
  5. Rocha I, Bras-Rosario L, Amparo-Barros M, Silva-Carvalho L: Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex. Exp Physiol. 2003 May;88(3):309-14. [PubMed:12719755]
  6. Guan J, Cheng DY, Chen XJ, Zhang Y, Wang H, Su QL: [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Nov;35(6):774-7. [PubMed:15573751]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. [PubMed:11823761]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase c binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A10
Uniprot ID
Q9HAW8
Uniprot Name
UDP-glucuronosyltransferase 1-10
Molecular Weight
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The major substrates of this isozyme are eugenol > 4-methylumbe...
Gene Name
UGT2B17
Uniprot ID
O75795
Uniprot Name
UDP-glucuronosyltransferase 2B17
Molecular Weight
61094.915 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
  2. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716]
  3. Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43. [PubMed:10725273]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Urate transmembrane transporter activity
Specific Function
Required for efficient urate re-absorption in the kidney. Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions.
Gene Name
SLC22A12
Uniprot ID
Q96S37
Uniprot Name
Solute carrier family 22 member 12
Molecular Weight
59629.57 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sugar:proton symporter activity
Specific Function
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name
SLC2A9
Uniprot ID
Q9NRM0
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 9
Molecular Weight
58701.205 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:02